e-space
Manchester Metropolitan University's Research Repository

    Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals

    Buongiorno, Mariateresa ORCID logoORCID: https://orcid.org/0000-0002-1745-5744, Sánchez-Benavides, Gonzalo, Marzal-Espí, Clara, Giraldo, Darly Milena, Krupinski, Jerzy ORCID logoORCID: https://orcid.org/0000-0002-5136-8898, Cullell, Natalia, Grau-Rivera, Oriol, Suárez-Calvet, Marc, Gispert, Juan Domingo and de la Sierra, Alex (2024) Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals. Journal of Alzheimer’s Disease, 102 (4). pp. 975-980. ISSN 1875-8908

    [img]
    Preview
    Accepted Version
    Available under License Creative Commons Attribution.

    Download (385kB) | Preview

    Abstract

    β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown. We compared cerebrospinal fluid (CSF) AD biomarker levels among non-demented individuals taking low, intermediate, or high BBB permeable β-blockers in two samples (ADNI: n = 216; EPAD: n = 79). We found that CSF amyloid-β levels were higher in individuals taking highly permeable β-blockers in the ADNI sample. This result was not replicated in EPAD, in which diminished levels of pTau181 and tTau were observed. These data suggest that β-blockers may impact AD pathophysiology.

    Impact and Reach

    Statistics

    Activity Overview
    6 month trend
    1Download
    6 month trend
    5Hits

    Additional statistics for this dataset are available via IRStats2.

    Altmetric

    Repository staff only

    Edit record Edit record